MetaCap

Palvella Therapeutics (PVLA) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palvella Therapeutics (PVLA) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 51.8% versus a loss of 29.2%. Over five years, PVLA leads with a -48.4% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.09 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PVLA+51.82%RCUS-29.16%
+93%+29%-35%
Nov 21, 20251 yearNov 20, 2026
PVLA-51.61%RCUS-67.15%
+7%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PVLA versus RCUS key metrics
MetricPVLARCUS
Share price$142.85$15.62
Market cap$2.09B$2.25B
1-day change-2.00%-1.01%
YTD return+36.48%-34.45%
1-year return+51.82%-29.16%
5-year return-48.39%-66.31%
EPS (TTM)$-5.53$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$247.00M
Revenue growth (YoY)—-4.26%
Net income (latest FY)$-41.72M$-353.00M
Operating margin—-156.28%
Net margin—-142.91%
52-week high$179.95$31.74
52-week low$72.23$15.56
Distance from 52-week high-20.62%-50.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+63.42%+162.48%
Average volume240.41K1.85M
Shares outstanding14.62M143.99M
Employees29601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PVLA has outperformed RCUS by 81.0 percentage points over the past year.

About Palvella Therapeutics

PVLA stock →

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

PVLA vs RCUS FAQ

Which is bigger, Palvella Therapeutics or Arcus Biosciences?

Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.09B for Palvella Therapeutics (PVLA).

Which stock has performed better over the past year, PVLA or RCUS?

PVLA returned +51.82% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are Palvella Therapeutics and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons